Immunology Division, CSIR-Institute of Microbial Technology , Chandigarh, India.
Host-Pathogen Interactions Program, Texas Biomedical Research Institute , San Antonio, TX, USA.
Autophagy. 2020 Jun;16(6):1021-1043. doi: 10.1080/15548627.2019.1658436. Epub 2019 Sep 8.
Host-directed therapies are gaining considerable impetus because of the emergence of drug-resistant strains of pathogens due to antibiotic therapy. Therefore, there is an urgent need to exploit alternative and novel strategies directed at host molecules to successfully restrict infections. The C-type lectin receptor CLEC4E and Toll-like receptor TLR4 expressed by host cells are among the first line of defense in encountering pathogens. Therefore, we exploited signaling of macrophages through CLEC4E in association with TLR4 agonists (C.T) to control the growth of (). We observed significant improvement in host immunity and reduced bacterial load in the lungs of infected mice and guinea pigs treated with C.T agonists. Further, intracellular killing of was achieved with a 10-fold lower dose of isoniazid or rifampicin in conjunction with C.T than the drugs alone. C.T activated MYD88, PtdIns3K, STAT1 and RELA/NFKB, increased lysosome biogenesis, decreased and gene expression and enhanced macroautophagy/autophagy. Macrophages from autophagy-deficient ( knockout or knockdown) mice showed elevated survival of . The present findings also unveiled the novel role of CLEC4E in inducing autophagy through MYD88, which is required for control of growth. This study suggests a unique immunotherapeutic approach involving CLEC4E in conjunction with TLR4 to restrict the survival of through autophagy.
3MA: 3 methyladenine; AO: acridine orange; Atg5: autophagy related 5; AVOs: acidic vesicular organelles; BECN1: beclin 1, autophagy related; BMDMs: bone marrow derived macrophages; bw: body weight; C.T: agonists of CLEC4E (C/TDB) and TLR4 (T/ultra-pure-LPS); CFU: colony forming unit; CLEC4E/Mincle: C-type lectin domain family 4, member e; CLR: c-type lectin receptor; INH: isoniazid; LAMP1: lysosomal-associated membrane protein 1; Mφ: infected C.T stimulated macrophages; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MDC: monodansylcadaverine; MTOR: mechanistic target of rapamycin kinase; MYD88: myeloid differentiation primary response 88; NFKB: nuclear factor of kappa light polypeptide gene enhance in B cells; NLR: NOD (nucleotide-binding oligomerization domain)-like receptors; PFA: paraformaldehyde; PPD: purified protein derivative; PtdIns3K: class III phosphatidylinositol 3-kinase; RELA: v-rel reticuloendotheliosis viral oncogene homolog A (avian); RIF: rifampicin; RLR: retinoic acid-inducible gene-I-like receptors; TDB: trehalose-6,6´-dibehenate; TLR4: toll-like receptor 4; Ultra-pure-LPS: ultra-pure lipopolysaccharide-EK; V-ATPase: vacuolar-type H ATPase.
由于抗生素治疗导致病原体产生耐药菌株,宿主导向疗法受到了极大的推动。因此,迫切需要利用针对宿主分子的替代和新颖策略来成功限制感染。宿主细胞表达的 C 型凝集素受体 CLEC4E 和 Toll 样受体 TLR4 是宿主抵御病原体的第一道防线。因此,我们通过 CLEC4E 与 TLR4 激动剂(C.T)联合利用巨噬细胞信号传导来控制()的生长。我们观察到用 C.T 激动剂治疗感染的小鼠和豚鼠后,宿主免疫得到了显著改善,肺部细菌载量减少。此外,与单独使用药物相比,在用 C.T 联合使用异烟肼或利福平时,()的细胞内杀伤作用提高了 10 倍。C.T 激活了 MYD88、PtdIns3K、STAT1 和 RELA/NFKB,增加了溶酶体生物发生,降低了和基因表达,并增强了巨自噬/自噬。自噬缺陷( knockout 或 knockdown)小鼠的巨噬细胞中()的存活率升高。本研究还揭示了 CLEC4E 通过 MYD88 诱导自噬的新作用,这对于控制()的生长是必需的。这项研究表明了一种独特的免疫治疗方法,涉及 CLEC4E 与 TLR4 联合使用,通过自噬来限制()的存活。
3MA:3-甲基腺嘌呤;AO:吖啶橙;Atg5:自噬相关 5;AVOs:酸性液泡器官;BECN1:自噬相关 5,beclin 1;BMDMs:骨髓来源的巨噬细胞;bw:体重;C.T:CLEC4E(C/TDB)和 TLR4(T/ultra-pure-LPS)激动剂;CFU:集落形成单位;CLEC4E/Mincle:C 型凝集素结构域家族 4 成员 E;CLR:C 型凝集素受体;INH:异烟肼;LAMP1:溶酶体相关膜蛋白 1;Mφ:感染 C.T 刺激的巨噬细胞;MAP1LC3/LC3:微管相关蛋白 1 轻链 3;MDC:单丹磺酰尸胺;MTOR:雷帕霉素靶蛋白激酶;MYD88:髓样分化初级反应 88;NFKB:κ 轻链增强子核因子 B 细胞;NLR:核苷酸结合寡聚化结构域样受体;PFA:多聚甲醛;PPD:纯化蛋白衍生物;PtdIns3K:III 类磷酸肌醇 3-激酶;RELA:v-rel 网状内皮细胞增生病病毒癌基因同源物 A(禽);RIF:利福平;RLR:视黄酸诱导基因-I 样受体;TDB:海藻糖-6,6'-二硬脂酸酯;TLR4:Toll 样受体 4;Ultra-pure-LPS:超纯脂多糖-EK;V-ATPase:液泡型 H ATP 酶。